01Does a candidate activate or inhibit a receptor pathway?
Evidence to Measure
Agonist & Antagonist DiscoveryReporter, second messenger, phosphorylation, trafficking, or another receptor-linked response.
Creative Biolabs designs functional phage display screening around the biological readout that defines success, connecting selection, candidate triage, and independent confirmation for target-defined and phenotype-first programs.
Functional phage display screening is most useful when the next research decision depends on biological activity rather than binding alone. At Creative Biolabs, we connect selection, functional triage, and independent confirmation so enriched candidates are evaluated against the readout that matters to your program.
We support both target-defined and phenotype-first projects. Choose the route closest to the outcome you need; if your question falls between standard routes, we can tailor the screening context, controls, and functional readout with you.
Identify receptor-binding candidates and test the direction of functional modulation.
Connect target binding with enzyme activity, dose-response, and selectivity evidence.
Move from checkpoint binding to competition, signaling, and immune-cell function.
Distinguish state-selective binding from apoptosis- or senescence-related phenotype modulation.
Evaluate endothelial, migration, invasion, adhesion, or ECM-associated function.
Discover state-selective ligands or candidates that alter a defined differentiation trajectory.
Identify candidates that restore response under a defined drug or perturbation condition.
Prioritize antibody candidates under tissue-access, circulation, or in vivo selection constraints.
If your endpoint does not fit a standard route, we can tailor the screening context, controls, and functional readout around your biological question.
Consult an ExpertA functional program should start from the readout that changes your next research decision. Use the guide below to connect your biological question with the evidence to measure and the screening route that best fits it.
Reporter, second messenger, phosphorylation, trafficking, or another receptor-linked response.
Substrate-to-product conversion, kinetic signal, concentration-response, and related-enzyme comparison.
Competition, target-dependent reporter, and immune-cell function as needed.
Phenotype-specific marker combinations with viability, proliferation, and timing controls.
Endothelial or tumor-cell functional assays paired with viability and matrix controls.
State-selective binding, lineage marker panels, proliferation/viability, and lineage function when needed.
Combination-response or re-sensitization readout with binder-only, drug-only, and untreated controls.
In vivo recovery, tissue distribution, or model-specific enrichment followed by independent confirmation.
Traditional phage display screening is often optimized to enrich binders. Functional phage display screening adds a second question: does the selected candidate alter the biological process that matters to the project? The two approaches are complementary rather than interchangeable.
Functional screening does not require every biological response to be physically coupled to a panning round. We choose the route that keeps the biology interpretable and the screening pressure technically realistic.
Both starting points can lead to useful functional candidates, but they require different controls and different expectations at handoff.
The screening environment should preserve the biology required for both selection and downstream validation. We use the simplest context that can answer the decision question and add complexity only when it contributes new information.
Useful for enzyme activity, molecular competition, interaction blocking, and controlled biochemical counterselection.
Preserves membrane topology, receptor density, glycosylation, uptake, signaling, and other cellular context.
Adds primary-sample or tissue-selectivity context when cultured cell lines do not capture the key biological contrast.
Used when access, circulation, tissue distribution, or organ-level context must influence selection.
We tailor the exact workflow to the assay and endpoint, but most projects follow the same evidence logic from biological question to functional confirmation.
We define the desired response and confirm assay suitability, including controls, model context, assay window, and evidence needed at handoff.
We match peptide, scFv, Fab, VHH, or another format to a protein-, cell-, ex vivo-, or in vivo-based screening environment.
We apply appropriate binding or functional pressure and track recovery and sequence-family behavior without treating abundance as proof of function.
Prioritized candidates are synthesized or re-expressed outside the phage particle and tested in a functional assay matched to the intended use.
We add target-negative controls, related targets, concentration-response, orthogonal assays, or mechanism studies when they will change the next research decision.
For high-throughput pool analysis, phage display NGS can support sequence-family tracking across rounds or conditions. We use those data for prioritization and carry selected candidates into independent binding and functional experiments before assigning a biological label.
You do not need to have every parameter finalized before contacting us. Start with the biological decision you need to make, and we can help define the screening and confirmation plan around it.
Biological objective and desired functional direction.
Known target or phenotype-first status; model and species.
Positive/negative controls, counter-targets, or control cell states.
Preferred library or candidate format and downstream use.
Existing assay readout, reference modulator, and evidence needed at handoff.
Screening design and assay-suitability summary.
Round-level enrichment data, clone or NGS sequences, and ranked families.
Independent binding and specificity results.
Functional triage, concentration-response, or phenotype data.
Non-phage confirmation and a staged recommendation for mechanism or target identification.
Lisowska and colleagues screened a combinatorial peptide phage library against ubiquitin and used next-generation sequencing to prioritize enriched sequences before synthesizing selected peptides for functional testing. In a reconstituted ubiquitination system, peptides 12 and 37 reproducibly inhibited ubiquitination, whereas another ubiquitin-binding peptide, peptide 44, was inactive. The study illustrates why target recognition and functional modulation should be treated as related but non-equivalent outcomes.
That distinction is central to our functional-screening strategy. Enrichment can nominate sequence-defined candidates, but advancement should be based on the assay that corresponds to the intended biological question and, when appropriate, repeated outside the phage particle. This staged approach helps preserve useful binders without prematurely labeling every enriched clone as bioactive.
Share your target status, model, functional readout, and downstream goal. We will help you choose a suitable screening route and define the controls and confirmation steps needed for your next research decision.
Discuss Your ProjectPlease kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
